Financial Performance - The company's total revenue for 2023 is approximately ¥408.05 million, a decrease of 7.71% compared to the previous year[4] - Net profit attributable to shareholders is approximately ¥102.32 million, showing a slight increase of 0.24% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is approximately ¥88.29 million, representing a growth of 12.10% compared to the previous year[4] - The basic earnings per share remain stable at ¥0.70, unchanged from the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period are approximately ¥878.19 million, an increase of 4.28% year-on-year[5] - Shareholders' equity attributable to the company is approximately ¥754.69 million, reflecting a growth of 6.62% compared to the beginning of the period[5] Cost Management and Operations - The company has improved its cost management, resulting in a 5% decrease in cost expense ratio and a 34% reduction in the average procurement price of key raw materials[8] - The company has successfully turned around its subsidiary, Kunming Zimuongong, achieving profitability[7] Product Development and Sales - New products such as Benzylpiperazine and Akapofen have shown significant growth, while the company is expanding its OTC channel and enhancing its online sales system[7][8] Cautionary Note - The company warns that the financial data presented is preliminary and has not been audited, urging investors to be cautious[9]
梓橦宫(832566) - 2023 Q4 - 年度业绩